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A 41-year-old female presented to the hospital with sore throat and shortness of breath. She was hypoxic with an oxygen saturation
of 87% in room air. Physical examination revealed swollen uvula with exudates. She had been started on topiramate for treatment
of migraine few months ago. &e dose of topiramate was increased to 100mg twice daily 2 weeks ago. Complete blood count
revealed an absolute neutrophil count (ANC) of 8 c/mm3. She was intubated and started on broad-spectrum antibiotics. She was
transferred to our hospital on the 5fth day of hospitalization. On arrival, her absolute neutrophil count was 10 c/mm3. Her
agranulocytosis was attributed to topiramate after ruling out other possible causes. ANC improved after topiramate was stopped.
ANC increased to 1000 after 5 days of stopping topiramate. We also reviewed published cases of topiramate-associated
agranulocytosis. Agranulocytosis is a rare side e;ect of topiramate, and only 3 case reports have been published so far. In all
cases, agranulocytosis developed after months of topiramate therapy and when dose was increased to 200mg daily suggesting
a dose-dependent e;ect. Next steps would be further research on the pathogenesis of agranulocytosis associated with topiramate
and creation of registry for data synthesis.
1. Introduction
Topiramate is a novel anticonvulsant with multiple mecha-
nisms of action including inhibition of voltage-activated
sodium and calcium channels, augmentation of GABA re-
ceptors, and inhibition of carbonic anhydrase [1]. It is used to
treat focal as well as generalized seizures. In addition, it is FDA
approved for migraine prophylaxis and weight loss phar-
macotherapy in combination with phentermine [1]. &e main
side e;ects of topiramate include cognitive slowing, word-
5nding diCculty, and impaired executive function [2]. Other
common adverse e;ects are sedation and weight loss [2].
Agranulocytosis is severe reduction in neutrophil count less
than 500 cells/mm [3, 4]. Agranulocytosis is drug induced
in 70% of cases [5]. Some of the commonly associated drugs
include clozapine, diclofenac, carbamazepine, vancomycin,
trimethoprim/sulfamethoxazole, beta-lactam antibiotics,
levamisole, and ticlopidine [5]. Agranulocytosis is a rare
side e;ect of topiramate. In our article, we describe a case
of agranulocytosis associated with topiramate and then
review cases of agranulocytosis or leucopenia associated
with topiramate.
2. Case Report
A 41-year-old female with a past medical history of Sjogren
syndrome, asthma, migraines, and generalized seizures well
controlled with medications was admitted to the intensive
care unit after transfer from an outside hospital. She had
presented to the outside hospital 5 days ago with sore throat,
trouble speaking, and shortness of breath. Her family noticed
that, over the last several days, she had been more confused
and brought her to the emergency department for evaluation.
On presentation, she was hypoxic with an oxygen saturation
level of 87% in room air, temperature of 101.2 F, pulse of
110/minute, and blood pressure of 100/60mmHg. Physical
examination revealed swollen uvula without exudates. Be-
cause of her mental status and hypoxia, she was intubated and
transferred to the outside hospital’s intensive care unit for
further care. &e rest of the physical examination was within
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normal limits. On review of hermedications, it was found that
she had been treated with Plaquenil on an outpatient setting
which was discontinued a month ago. She was started on
topiramate for treatment of migraine by her neurologist few
months ago.&e dose of the topiramate had been increased to
100mg twice a day 2 weeks ago. Rest of her medications
included tramadol as needed and an albuterol inhaler.
Complete blood count revealed an absolute neutrophil count
(ANC) of 8 c/mm3. Blood and throat cultures were sent, and
she was started on broad-spectrum antibiotics, including
vancomycin, piperacillin-tazobactam, and clindamycin.
Streptococcus pyogenes and Hemophilus in$uenzae were iso-
lated from throat, and her blood culture was found to be
positive for Escherichia coli.
When she arrived at our hospital on her hospital day 5,
she was still intubated. Her ANC was 10 c/mm3. Labs were
signi5cant for negative polymerase chain reaction (PCR) for
Epstein–Barr virus (EBV), cytomegalovirus (CMV), human
immunode5ciency virus (HIV), hepatitis B virus (HBV), and
hepatitis C virus (HCV). &e vitamin B12 level was 600 ng/L
(normal 180–914 ng/L). &e folate level in blood was
12 ng/mL (normal 2–20 ng/mL). Flow cytometry of pe-
ripheral blood leucocytes showed T-cell population (about
50% of the cells analyzed) with no aberrant loss or aberrant
expression of T-cell markers, a B-cell population (about 45%
of the cells analyzed) that was negative for CD5 and CD10,
and no surface light-chain restriction. &e analyzed cells
were negative for CD34, CD13, and CD33. Hematology
services was consulted which did not think her agranulo-
cytosis was due to primary bone marrow problem and
recommended no need for bone marrow biopsy. Topiramate
had been held from hospital day 1. Broad-spectrum antibi-
otics were continued. She also received 1 dose of granulocyte-
monocyte colony-stimulating factor (GM CSF) on hospital
day 6. Her neutrophil count started improving, and ANC was
1000 on the eleventh day of hospitalization.
3. Discussion
In our case, the probability of causal relationship of agran-
ulocytosis and topiramate was assessed by the WHO-UMC
algorithm [6]. Because the low numbers of ANC did return
towards normal levels under continuous treatment, the
probablility that the agranulocytosis related to topiramate can
be rated only as probable.
In spite of the lack of evidence of eCcacy in drug-induced
neutropenia [7], granulocyte-monocyte colony-stimulating
factor (GM CSF) is used empirically at doses of 5mcg/kg
per day. Treatment with GM CSF can be discontinued when
the total white blood cell count exceeds 10,000/microL [8]. In
our case, it was not clear why she received a single injection of
GM CSF rather than daily injections.
Search done for cases of agranulocytosis/neutropenia/
leucopenia associated with topiramate in major databases
MEDLINE, Embase, and Cochrane Library revealed three
case reports [9–11].
In the case reported byMinakawa et al. [10], a 40-year-old
male with intractable frontal lobe epilepsy was started on
topiramate 100mg daily, eventually increased to 200mg/day
over 2 weeks. Other concurrent medications included phe-
nytoin and acetazolamide. He was found to have an absolute
neutrophil count of 440/mm3 on day 38 of topiramate
therapy. It was not mentioned whether the patient developed
any symptoms or signs from agranulocytosis. Topiramate
was decreased to 100mg/day and discontinued after a week
of agranulocytosis. He was on phenytoin during the entire
period. No further tests to rule out possible causes of
agranulocytosis were done as there was no reduction in
hemoglobin and platelets, and agranulocytosis resolved 5 days
after stopping topiramate.
Behar and Schaller [9] reported a case of a 28-year-old
male with a past medical history of bipolar disorder on
clozapine therapy who had topiramate added as a mood
stabilizer after the patient’s mother was concerned about his
weight gain on clozapine therapy. His white blood cell
(WBC) count had been stable on clozapine for 2 years.
Topiramate was added 25mg twice a day for 1 week, 50mg
twice a day for 1 week, 100mg twice a day for 1 week, and
then 200mg twice a day. He was followed with complete
blood count every 2 weeks. He developed leucopenia
(WBC count of less than 4000/mm3) after 1 week of topiramate
200mg twice a day. His WBC count was 3700/mm3 after
a week. Clozapine was stopped at that time. HisWBC dropped
to 3700/mm3 on the seventeenth day and 3100/mm3 on day 22
of topiramate therapy of 200mg twice daily. He started having
manic symptoms after clozapine was stopped. His family
withdrew objection to weight gain, and topiramate was
stopped. He was restarted on clozapine. His WBC count
was 11,500/mm3 a week o; topiramate and on clozapine.
His manic symptoms resolved.
Sharma et al. [11] reported a case of a 23-year-old male
with diagnosis of paranoid schizophrenia on clozapine
therapy at a dose of 300mg daily. He was started on top-
iramate due to concern for weight gain on clozapine therapy.
Topiramate was started at 25mg daily for a week, 50mg daily
for 2 weeks, and then 100mg daily. He continued clozapine
300mg/day and topiramate 100mg/day for eight months
during which time his white cell count remained under
normal limits. After eight months, topiramate was increased
to 200mg per day as he was still gaining weight.&e patient’s
dose of clozapine was not changed. On the 57th day of
therapy, with topiramate 200mg daily along with clozapine
300mg/day, his absolute neutrophil count was 1200/mm3.
Clozapine was discontinued. It was not mentioned whether
he developed any clinical features from reduction in neu-
trophils. After 2 days of stopping clozapine, topiramate was
tapered o;. He was started on olanzapine and lithium
therapy. ANC returned to normal limits. It was not clear
how long it took for ANC to return to normal after stopping
topiramate. &is case is less clearly related to topiramate as
clozapine also may cause agranulocytosis.
Agranulocytosis is a rarely reported side e;ect of top-
iramate, and its true incidence is unknown. Few cases have
been reported in the medical literature. In a systematic
review published by Andersohn et al. [4], 980 cases of
nonchemotherapy drug-induced agranulocytosis from
1966 to 2006 were reported. &ere was not a single case of
topiramate-associated agranulocytosis in the systematic review.
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However, sulfonamides including carbonic anhydrase in-
hibitors to which topiramate also belongs to are among the
most commonly reported drugs for causing hematological
disorders [12].
Drug-induced agranulocytosis can occur via multiple
mechanisms. Two of the most commonly cited mechanisms
include immunogenic e;ects (via generation of an oxidative
metabolite that stimulates T cells to attack the marrow) and
direct toxicity of the drug to the bone marrow [7]. &e
pathogenesis of agranulocytosis associated with topiramate
is not clear. In cases of immune-mediated neutropenia/
agranulocytosis, neutrophil count usually drops rapidly
within 5 to 7 days of drug administration [3]. Immune-
mediated agranulocytosis is often accompanied by rash and
fever as seen in cases of agranulocytosis associated with beta-
lactam antibiotics, which was not seen in our case or any of
the reviewed cases [3]. Topiramate (sulfamate) is structurally
similar to sulfones (dapsone) and sulfonamides (acetazolamide,
sulfonylureas, and sulfamethoxazole). Dapsone causes agran-
ulocytosis due to the toxic action of its metabolites against
neutrophils and bone marrow [13]. In our case as well as in the
other reported cases, reduction in neutrophil count was de-
tected after months of topiramate therapy. In the reported
cases, neutrophil count decreased when the dose of topiramate
was increased to 200mg daily, suggesting a dose-dependent
e;ect. No reduction in neutrophil count was seen with doses
less than 200mg daily [11]. &ese all suggest that topiramate-
associated reduction in neutrophil count is most likely sec-
ondary to toxic e;ects of the drug. However, further research is
required in future to elucidate the mechanism of topiramate-
associated agranulocytosis.
4. Conclusion
Topiramate is a broad-spectrum novel anticonvulsant used
for seizure treatment, migraine prophylaxis, and weight loss.
Agranulocytosis/neutropenia is a rare side e;ect of top-
iramate and is limited to few case reports. &e pathogenesis
of reduction in neutrophil count associated with topiramate
is not entirely known. In our case as well as in other
published cases, reduction in neutrophil count occurred
after months of topiramate therapy and at doses greater than
or equal to 200mg daily. In all cases, neutrophil count
returned to normal after topiramate was stopped. Next steps
would be further research on the pathogenesis of agranu-
locytosis associated with topiramate and creation of registry
for data synthesis.
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